Compare UIS & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UIS | KROS |
|---|---|---|
| Founded | 1942 | 2015 |
| Country | United States | United States |
| Employees | N/A | 87 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.2M | 206.0M |
| IPO Year | 1994 | 2020 |
| Metric | UIS | KROS |
|---|---|---|
| Price | $3.53 | $10.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $5.67 | ★ $21.86 |
| AVG Volume (30 Days) | ★ 1.1M | 225.1K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,950,100,000.00 | $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.60 | $2,751.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.97 | $9.69 |
| 52 Week High | $4.98 | $22.55 |
| Indicator | UIS | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 47.40 | 50.88 |
| Support Level | $3.51 | $10.64 |
| Resistance Level | $4.06 | $12.43 |
| Average True Range (ATR) | 0.30 | 0.44 |
| MACD | -0.10 | 0.04 |
| Stochastic Oscillator | 3.64 | 69.59 |
Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. maximum of revenue is from CA&I segment.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.